Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Evan C Ewers; Phalgoon A Shah; Mark G Carmichael; Tomas M Ferguson

doi:10.1093/ofid/ofw223

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Open Forum Infect Dis. 2016 Dec 20;3(4):ofw223. doi: 10.1093/ofid/ofw223. eCollection 2016 Oct.

Authors

Evan C Ewers¹, Phalgoon A Shah¹, Mark G Carmichael², Tomas M Ferguson³

Affiliations

¹ Department of Medicine.
² Section of Hematology/Oncology, Department of Medicine, and.
³ Section of Infectious Diseases, Department of Medicine, Tripler Army Medical Center , Honolulu, Hawaii.

Abstract

Hepatitis C virus (HCV) infection is associated with the development of non-Hodgkin lymphomas. For aggressive lymphomas, such as diffuse large B-cell lymphoma (DLBCL), treatment of HCV infection is typically deferred in treatment-naive patients until after completion of lymphoma therapy [1, 2]. We report a case of HCV-associated stage IV DLBCL successfully treated concurrently using chemoimmunotherapy and a sofosbuvir-based antiviral regimen.

Keywords: DLBCL; Hepatitis C Virus; Lymphoma; Sofosbuvir..